Supernus Pharmaceuticals, Inc. (LON:0LB2)
33.25
+0.84 (2.59%)
At close: Jul 10, 2025
Supernus Pharmaceuticals Revenue
Supernus Pharmaceuticals had revenue of $149.82M USD in the quarter ending March 31, 2025, with 4.30% growth. This brings the company's revenue in the last twelve months to $668.00M, up 11.82% year-over-year. In the year 2024, Supernus Pharmaceuticals had annual revenue of $661.82M with 8.94% growth.
Revenue (ttm)
$668.00M
Revenue Growth
+11.82%
P/S Ratio
2.96
Revenue / Employee
$991.09K
Employees
674
Market Cap
1.53B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 661.82M | 54.30M | 8.94% |
Dec 31, 2023 | 607.52M | -59.72M | -8.95% |
Dec 31, 2022 | 667.24M | 87.46M | 15.09% |
Dec 31, 2021 | 579.78M | 59.38M | 11.41% |
Dec 31, 2020 | 520.40M | 127.64M | 32.50% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Supernus Pharmaceuticals News
- 15 days ago - Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma - Benzinga
- 22 days ago - SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE - Business Wire
- 23 days ago - These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga
- 24 days ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc. - PRNewsWire
- 24 days ago - S&P 500 Surges 1%; New York Manufacturing Activity Tumbles In June - Benzinga
- 24 days ago - Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday - Benzinga
- 24 days ago - Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal - Benzinga
- 24 days ago - Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million - Investor's Business Daily